Curis | CRIS - Selling And Administration Expenses


Curis reported $4.79M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 585K 260K Sep/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bayer EUR 4.05B 647M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
CSL USD 1.23B 498M Dec/2025
Curis USD 4.79M 100K Jun/2024
Eli Lilly USD 3.13B 391.3M Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
TG Therapeutics USD 50.73M 12.64M Dec/2025
Verastem USD 12.28M 2.06M Sep/2024
Xoma USD 11M 2.54M Jun/2024